Left atrial appendage occlusion (LAAO) has evolved from a niche option for oral anticoagulation–intolerant patients to a frontline procedural strategy for stroke prevention in atrial fibrillation. Landmark trials like OPTION, SWISS‑APERO, and COMBINATION are redefining how and when we use these devices.

In this episode of EP Edge, Dr. Niraj Sharma walks through the historical arc of LAAO, key evidence shaping contemporary practice, procedural complications often under-recognized (like silent cerebral lesions), and where the field is headed with AI, new device designs, and competition from Factor XI inhibitors.

This is essential listening for electrophysiologists, interventional cardiologists, and rhythm specialists navigating the next era of stroke prevention.

For: Source data/infographics see EPEDGE Newsletter on LinkedIn
For feedback, collaborations, or questions, email Dr. Niraj Sharma at [email protected] or connect on LinkedIn